Email This Release
Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed (ALIMTA®) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study
*
marks required fields
Recipient Name:
*
Recipient Email:
Message:
*
Enter security words:
Get Business Wire News on Your Website
Terms of Use
|
© 2024 Business Wire